Literature DB >> 17621626

Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia.

Birgit Kainz1, Medhat Shehata1,2, Martin Bilban3, Dirk Kienle4, Daniel Heintel1, Elisabeth Krömer-Holzinger5, Trang Le1, Alexander Kröber4, Gerwin Heller6, Ilse Schwarzinger3, Dita Demirtas1,2, Andreas Chott7, Hartmut Döhner4, Sabine Zöchbauer-Müller6, Christa Fonatsch5, Christoph Zielinski6,8, Stephan Stilgenbauer4,9, Alexander Gaiger1, Oswald Wagner3,8, Ulrich Jäger1,8,9.   

Abstract

We report high expression of the maternally imprinted gene PEG10 in high-risk B-CLL defined by high LPL mRNA expression. Differential expression was initially identified by microarray analysis and confirmed by real time PCR in 42 B-CLL patients. mRNA expression ranged from 0.3- to 375.4-fold compared to normal peripheral blood mononuclear cells (PBMNC). Expression levels in CD19+ B-CLL cells were 100-fold higher than in B-cells from healthy donors. PEG10 expression levels in B-CLL patient samples remained stable over time even after chemotherapy. High PEG10 expression correlated with high LPL expression (p=0.001) and a positive Coombs' test (p=0.04). Interestingly, similar expression patterns were observed for the neighbouring imprinted gene sarcoglycan-epsilon (SGCE). Monoallelic expression and maintained imprinting of PEG10 were found by allele- or methylation-specific PCR. The intensity of intracellular staining of PEG10 protein corresponded to mRNA levels as confirmed by immunofluorescence staining. Short term knock-down of PEG10 in B-CLL cells and HepG2 cells was not associated with changes in cell survival but resulted in a significant change in the expression of 80 genes. However, long term inhibition of PEG10 led to induction of apoptosis in B-CLL cells. Our data indicate (i) a prognostic value of PEG10 in B-CLL patients; (ii) specific deregulation of the imprinted locus at 7q21 in high-risk B-CLL; (iii) a potential functional and biological role of PEG10 protein expression. Altogether, PEG10 represents a novel marker in B-CLL. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17621626     DOI: 10.1002/ijc.22929

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.

Authors:  Dirk Kienle; Axel Benner; Carolin Läufle; Dirk Winkler; Christof Schneider; Andreas Bühler; Thorsten Zenz; Annett Habermann; Ulrich Jäger; Peter Lichter; Riccardo Dalla-Favera; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

Review 2.  Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.

Authors:  Teodora Ribarska; Klaus-Marius Bastian; Annemarie Koch; Wolfgang A Schulz
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

3.  Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity.

Authors:  Wei Peng; Hong Fan; Guoqiu Wu; Jianzhong Wu; Jifeng Feng
Journal:  Clin Exp Med       Date:  2015-04-12       Impact factor: 3.984

4.  Domesticated transposable element gene products in human cancer.

Authors:  Jesse D Riordan; Adam J Dupuy
Journal:  Mob Genet Elements       Date:  2013-10-14

5.  Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma.

Authors:  Dong-cai Liu; Zhu-lin Yang; Song Jiang
Journal:  Pathol Oncol Res       Date:  2011-04-01       Impact factor: 3.201

6.  Upregulation of imprinted genes in mice: an insight into the intensity of gene expression and the evolution of genomic imprinting.

Authors:  Ismail Zaitoun; Karen M Downs; Guilherme J M Rosa; Hasan Khatib
Journal:  Epigenetics       Date:  2010-03-01       Impact factor: 4.528

7.  PEG10 amplification at 7q21.3 potentiates large-cell transformation in cutaneous T-cell lymphoma.

Authors:  Fengjie Liu; Yumei Gao; Bufang Xu; Shan Xiong; Shengguo Yi; Jingru Sun; Zhuojing Chen; Xiangjun Liu; Yingyi Li; Yuchieh Lin; Yujie Wen; Yao Qin; Shuxia Yang; Hang Li; Trilokraj Tejasvi; Lam Tsoi; Ping Tu; Xianwen Ren; Yang Wang
Journal:  Blood       Date:  2022-01-27       Impact factor: 22.113

8.  Gene expression profile analysis of human hepatocellular carcinoma using SAGE and LongSAGE.

Authors:  Hui Dong; Xijin Ge; Yan Shen; Linlei Chen; Yalin Kong; Hongyi Zhang; Xiaobo Man; Liang Tang; Hong Yuan; Hongyang Wang; Guoping Zhao; Weirong Jin
Journal:  BMC Med Genomics       Date:  2009-01-26       Impact factor: 3.063

9.  Genetic and molecular analyses of PEG10 reveal new aspects of genomic organization, transcription and translation.

Authors:  Heike Lux; Heiko Flammann; Mathias Hafner; Andreas Lux
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

10.  Aberrant promoter methylation and expression of the imprinted PEG3 gene in glioma.

Authors:  Susumu Otsuka; Shinji Maegawa; Ayumi Takamura; Hideki Kamitani; Takashi Watanabe; Mitsuo Oshimura; Eiji Nanba
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2009       Impact factor: 3.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.